Off-Label Drug Uses — This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Wolters Kluwer Health. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form, so the reader can easily identify the scope of information available. A summary of the data—including background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments regarding “Off-Label Drug Uses” to hospitalpharmacy@wolterskluwer.com.
Get full access to this article
View all access options for this article.
References
1.
PlettenbergH., AssmannT., RuzickaT.Childhood vitiligo and tacrolimus: immunomodulating treatment for an autoimmune disease. Arch Dermatol.2003; 139: 651–654.
2.
LepeV., MoncadaB., Castanedo-CazaresJ.P., Torres-AlvarezM.B., OrtizC.A., Torres-RubalcavaA.B.A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol.2003; 139: 581–585.
3.
PasseronT., OstovariN., ZakariaW.. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol.2004; 140: 1065–1069.
4.
KawalekA.Z., SpencerJ.M., PhelpsR.G.Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg.2004; 30(2 pt 1): 130–135.
5.
SilverbergN.B., LinP.. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol.2004; 51: 760–776.
6.
KanwarA.J., DograS., ParsadD.Topical tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol.2004; 29: 589–592.
7.
GrimesP.E., SorianoT., DytocM.T.Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol.2002; 47: 789–791.
8.
AhnB.K., KimB.D., LeeS.J., LeeS.H.Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment. J Am Acad Dermatol.2005; 52(3 pt 1): 532–533.
9.
Prats CaellesI., Herranz PintoP., de Ayala CasadoE.L., de Lucas LagunaR.Focal hypertrichosis during topical tacrolimus therapy for childhood vitiligo. Pediatr Dermatol.2005; 22: 86–87.
10.
TravisL.B., WeinbergJ.M., SilverbergN.B.Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol.2003; 139: 571–574.
11.
Castanedo-CazaresJ.P., LepeV., MoncadaB.Repigmentation of chronic vitiligo lesions by following tacrolimus plus ultraviolet-B-narrow band. Photodermatol Photoimmunol Photomed.2003; 19: 35–36.
12.
SmithD.A., TofterS.J., HanifinJ.M.Repigmentation of vitiligo with topical tacrolimus. Dermatology.2002; 205: 301–303.
13.
US Food and Drug Administration.FDA News. FDA approves updated labeling with boxed warning and medication guide for two eczema drugs, Elidel and Protopic. Available at: http://www.fda.gov/bbs/topics/news/2006/NEW01299.html.
14.
CoskunB., SaralY., TurgutD.Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol.2005; 15: 88–91.
15.
GrimesP.E.New insights and new therapies in vitiligo. JAMA.2005; 293: 730–735.
16.
KostovicK., PasicA.New treatment modalities for vitiligo: focus on topical immunomodulators. Drugs.2005; 65: 447–459.
17.
MayoralF.A., GonzalezC., ShahN.S., ArciniegasC.Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology.2003; 207: 322–323.
